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INTRODUCTION
Emergency clinicians manage a wide variety of 
complications associated with malignancy, including 
cardiovascular, gastrointestinal (GI), pulmonary, infectious, 
and other complications. Cancer therapies have expanded 
and improved over the last decade. Immune-based therapies 
function through a different set of mechanisms compared to 
prior therapies; thus, this class is associated with different 
complications.1-4 Medications and new therapeutic techniques 
are being continually introduced, and emergency clinicians must 
understand these medications and their complications. 
METHODS
This is a narrative review evaluating complications from 
current immune-based therapies in cancer. To complete this 
review on immune-based therapy complications, we undertook 
a literature search of PubMed, Google Scholar, and MEDLINE 
using search terms “immunotherapy,” “immune-based,” 
“checkpoint inhibitor,” “CAR T,” AND “malignancy” OR 
“cancer.” We included guidelines, randomized controlled trials, 
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Cancer therapies have undergone several recent advancements. Current cancer treatments include 
immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each 
treatment has the potential for complications that differ from chemotherapy and radiation. This 
review evaluates immune-based therapies and their complications for emergency clinicians. Therapy 
complications include immune-related adverse events (irAE), cytokine release syndrome (CRS), 
autoimmune toxicity, and chimeric antigen receptor (CAR) T-cell-related encephalopathy syndrome 
(CRES). Immune-related adverse events are most commonly encountered with checkpoint inhibitors 
and include dermatologic complications, pneumonitis, colitis/diarrhea, hepatitis, and endocrinopathies. 
Less common irAEs include nephritis, myocardial injury, neurologic toxicity, ocular diseases, and 
musculoskeletal complications. CRS and CRES are more commonly associated with CAR T-cell 
therapy. CRS commonly presents with flu-like illness and symptoms resembling sepsis, but severe 
myocardial and pulmonary disease may occur. Critically ill patients require resuscitation, broad-
spectrum antibiotics, and hematology/oncology consultation. [West J Emerg Med. 2020;21(3)566-580.]
cohort/observational studies, narrative reviews, and systematic 
reviews/meta-analyses. Studies were limited to English and 
adult patients. Our initial literature search revealed over 620 
resources. We excluded studies not focusing on emergency 
department (ED) evaluation and management, resulting in 
inclusion of 134 resources.
DISCUSSION
Besides Chemotherapy and Radiation, What Are Other 
Types of Cancer Therapies?
Immune-based therapies differ from cytotoxic chemotherapy 
in that immunotherapy works to break the body’s tolerance of 
the malignant cells. There are several immune-based strategies, 
each of which acts with different mechanisms (Table 1).1-3 
These treatments can be used in isolation or in combination with 
chemotherapy and/or radiation.2-6 However, these therapies can 
result in either autoimmune or cytokine-associated toxicities that 
are not seen with chemotherapy and radiation.
Interleukin-2 (IL-2) stimulates the growth of T-cells and 
natural killer cells, which engage malignant cells and target 
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What do we already know about this issue?
Current cancer treatments include immune-based 
therapies, comprised of checkpoint inhibitors and 
adoptive immunotherapy, each with the potential 
for complications.
What was the research question?
We evaluate immune-based therapies and their 
complications for emergency clinicians.
What was the major finding of the study?
Complications include immune-related adverse 
events, cytokine release syndrome, and CAR-
related encephalopathy syndrome. 
How does this improve population health?
Knowledge of the complications associated with 
immune-based therapies can improve emergency 
providers’ management of these patients. 
them for destruction by the immune system. IL-2 was first 
identified in 1980 and approved in the 1990s for metastatic 
melanoma and metastatic renal cell cancer, and it currently 
is used for non-small cell lung cancer as well.1,7-9 IL-2 has 
demonstrated efficacy in inducing regression in advanced solid 
cancers.7-9 While patient responses to therapy can be dramatic 
when they occur, the true response rate is quite low (objective 
response rate 15% and five-year overall survival 8% in one 
European series).10 Administration of high-dose IL-2 is done 
in the inpatient setting as it creates a systemic inflammatory 
response, often requiring fluids, vasopressors, and intensive 
monitoring. Few centers administer this therapy. Given the low 
rate of sustained remissions and high toxicity, the role of high 
dose IL-2 has substantially decreased with the development of 
checkpoint inhibitors. 
Checkpoint Inhibitors
Checkpoint inhibitors are monoclonal antibodies that impede 
the activity of inhibitory molecules on the surface of tumor cells 
that typically reduce immune response; they take the “brakes” 
off the immune system so that tumor cells can be recognized.2,11 
Clinical antibodies are available for three ligands: cytotoxic 
T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-
1), and programmed death ligand 1 (PDL-1) (Figure 1). In the 
absence of malignancy, receptors CTLA-4, PD-1/PD-2, and 
PDL-1 reduce T-cell proinflammatory response and decrease 
tissue damage from the immune system, improving self- 
tolerance.2,11-13 When cancers develop, malignant cells upregulate 
these receptors, which decreases immune system clearance of 
these cells. 
Checkpoint inhibitors activate T cells by blocking the 
action of these receptors, removing inhibitory signals and 
resulting in destruction of tumor cells.14-16 Inhibition of immune 
checkpoints can lead to T cells affecting nonmalignant cells, 
resulting in tissue injury and organ dysfunction.17,18 Checkpoint 
inhibitors, specifically ipilimumab, were first approved for 
metastatic melanoma, although the indications for these agents 
have drastically expanded, including small cell and non-small-
cell lung cancer, ovarian cancer, renal cell carcinoma, gastric 
and colorectal cancer, urothelial cancer, Hodgkin lymphoma, 
and others.2-4,19,20 These agents have demonstrated significant 
improvements in survival.4,21,22
Chimeric Antigen Receptor (CAR) Therapies
This method of adoptive immunotherapy uses genetically 
modified T cells with a chimeric antigen receptor (CAR) that 
targets malignant cells.23-27 The patient’s own T cells are obtained 
through leukapheresis and then modified ex vivo with a tumor-
specific receptor. The cells with the highest antitumor activity 
are selected for expansion. Following lymphocyte-depleting 
chemotherapy, the replicated T cells are then administered to the 
patient (Figure 2).23-27 The first CAR T-cell therapies included 
tisagenlecleucel and axicabtagene ciloleucel, approved in 2017 
for lymphoblastic leukemia and advanced lymphoma.23-34 The 
Food and Drug Administration-approved CAR T-cell therapies 
target CD19, a protein expressed on the surface of both malignant 
and normal B lymphocytes. CAR T-cells targeting a range of 
other proteins are currently under study for Hodgkin lymphoma, 
multiple myeloma, glioblastoma, melanoma, breast cancer, and 
sarcoma.23-34 Also under development are “natural killer” cells 
engineered in a similar way to recognize tumor cell antigens.
Class Mechanism Therapeutic agent
Stimulator Stimulates effector cells Interleukin-2
Checkpoint inhibitor Inhibits regulatory factors Anti-CTLA4 (ipilimumab), Anti-PD-1 (nivolumab, pembrolizumab), 
Anti-PD-L1 (atezolizumab, avelumab, durvalumab)
Adoptive 
immunotherapy
Activated immune cell passive 
transfer, which have antitumor activity
CAR T-cell (axicabtagene ciloleucel, tisagenlecleucel)
Table 1. Immune-based agents and mechanisms used in cancer therapy.1-3
CAR, chimeric antigen receptor; CTLA4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; PD-L1, 
programmed death-ligand 1. 
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What Can Go Wrong with These Therapies? 
As the mechanisms of these newer therapies, particularly 
checkpoint inhibitors and CAR T-cell therapy, significantly differ 
from normal chemotherapy, adverse effects and complications 
also differ.35-40 These complications are typically termed irAEs, 
which are a result of immune system over-activity, rather than 
a depleted immune system that occurs with chemotherapy. 
Immune-related adverse events most commonly affect systems 
with significant cell turnover.35-40 Most irAEs occur within 3-6 
months of starting therapy, but it should be noted that irAEs 
can occur at any time, even after the patient discontinues 
treatment.35-42 Of patients receiving an anti-CTLA-4 medication, 
60-90% experience an irAE, while 39-70% of those administered 
an anti-PD-1/PD-L1 medication experience an irAE.5,43-46 
While mortality is rare, morbidity associated with these 
agents can be severe.35-42 Immune-related adverse events 
associated with this class range in severity, based on a scale 
from the National Cancer Institute (NCI).47 This scale ranges 
from mild (1) to death (5), based on the Common Terminology 
Criteria for Adverse Events (CTCAE). Grades 1 and 2, or 
mild to moderate irAEs, occur frequently and can be treated 
symptomatically as outpatients. Grade 3 and 4 irAEs, while less 
frequent, can be severe and require admission (Table 2).47 The 
risk of irAEs and severity is greater with combination therapy, 
compared to monotherapy.48-51 Higher doses of ipilimumab 
and pembrolizumab are also associated with greater risk of 
irAEs.52-54 However, other anti-PD-1 and PD-LI medications 
do not demonstrate a dose-related response with irAE.19,35-40 
Interestingly, the occurrence of irAEs is associated with improved 
clinical outcomes in patients with malignancy.18
The most commonly encountered irAEs affect the 
GI, dermatologic, endocrine, and pulmonary systems. 
The cardiovascular, hematologic, renal, neurologic, and 
musculoskeletal systems are not as commonly affected.35-42 Colitis 
is associated with better prognosis compared to pneumonitis.55,56 
Dermatologic irAEs are typically seen two to three weeks after 
therapy initiation, followed by the GI system at six to seven 
weeks, and the endocrine system at nine to ten weeks.35-42,56 
Severe irAEs associated with anti-CTLA-4 medications occur 
earlier compared to anti-PD-1/PD-L1 medications.35-45 Laboratory 
and imaging assessment depend on the specific organ involved. 
Management focuses on systemic corticosteroids for the majority, 
except several endocrinopathies (Table 2).35-42,48,49 Clinicians 
should assess for infection and progression of the malignancy, 
which can present with similar symptoms as an irAE. With 
appropriate therapy, most irAEs, even grade 3-4, will resolve, 
except endocrinopathies.35-42,48,49  
Dermatologic
Dermatologic toxicities are some of the most common 
irAEs, especially in patients with melanoma, and are often 
seen early after starting therapy (two to three weeks).35-37,48,54 
Reactions may include maculopapular rash, bullae, 
maculopustular rash, vitiligo, Stevens-Johnson syndrome 
(SJS), toxic epidermal necrolysis (TEN), or drug reaction with 
eosinophilia and systemic symptoms. The differential includes 
Cancer Therapy by Inhibition of Negative 
Immune Regulation (CTLA4, PD1)
Tumor 
(e.g. Melanoma)
APC Containing TAA 
Migrates to Lymph Node
Lymph 
Node
Naïve
T-Cell
Tumor Microenvironment T-Cell Priming
Figure 1. Checkpoint inhibitor mechanisms (CTLA-4 and PD-1). 
Modified from https://commons.wikimedia.org/wiki/File:11_Hegasy_CTLA4_PD1_Immuntherapie.png. Accessed April 7, 2019.
CTLA4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; APC, antigen-
presenting cell; TAA, tumor-associated antigen; TCR, t-cell receptor; CD, cluster of differentiation.
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vasculitis, atopic/contact dermatitis, viral exanthem, drug 
toxicity, erythema multiforme, or infectious causes.35-45,55-58 
Physicians should evaluate the patient’s medication list, 
hemodynamics, systemic symptoms, mucosal involvement, 
and total body surface area involved. Laboratory assessment 
for patients with severe disease includes complete blood count 
(CBC) with differential, renal and liver function, coagulation 
panel, creatine kinase (CK), and electrolytes. Dermatology 
consultation is recommended. Most patients have grade 1-2 
rashes. Mild rashes can be treated with oral antihistamines and 
topical steroids, but for those with severe rashes (including SJS 
or TEN), systemic steroids are recommended.55-58 
Cardiac
A variety of cardiac effects can occur including dysrhythmias 
(blocks, supraventricular or ventricular tachycardias), myocarditis 
(new systolic heart failure and cardiogenic shock), Takotsubo 
cardiomyopathy, and pericarditis/myopericarditis.1-4,59,60 Patients 
should be evaluated with electrocardiogram, echocardiography 
(assessing ventricular function, wall abnormalities, cardiac 
effusion), thyroid stimulating hormone (TSH), troponin, and 
chest radiograph. Patients may require cardiac catheterization. 
Corticosteroid therapy is recommended for myocarditis and 
ventricular dysrhythmias due to irAE. Prednisone 1-2 milligrams 
per kilogram per day (mg/kg/day) (or its equivalent) for mild-
moderate disease is recommended, but in severe cardiac irAE 
or in patients who do not respond, methylprednisolone 1 gram 
intravenous (IV) per day is recommended.60-62 Other immunologic 
agents such as infliximab, mycophenolate mofetil, or 
antithymocyte globulin may be required.60-62 Dysrhythmias from 
cardiac conduction pathology may require pacemaker insertion. 
Heart failure should be treated with standard therapies. Pericardial 
tamponade requires IV fluid resuscitation and drainage. 
Pulmonary
Pneumonitis is the predominant irAE of the pulmonary 
system, ranging from no or mild symptoms to respiratory failure 
requiring intubation and ventilatory support.1-5 Pneumonitis is 
the most common irAE requiring discontinuation of checkpoint 
inhibitor therapy, as well as the most common cause of death 
related to irAE.63-65 Dyspnea, cough, fever, and chest pain may 
be present, with dyspnea occurring in 53% and cough in 35% 
of patients.40,63-65 Productive cough is rare and suggests another 
diagnosis.40 The differential includes infection (opportunistic 
infection, pneumonia), heart failure (myocarditis), pulmonary 
embolism, extension of the malignancy, underlying interstitial 
lung disease or obstructive disease, diffuse alveolar hemorrhage, 
neuromuscular disease, or pneumonitis due to other therapies. 
Laboratory assessment includes CBC, electrolytes, 
blood cultures, and urine testing for pneumococcal and 
legionella antigens. Sputum cultures and gram stain are also 
recommended, although these can be obtained in the critical 
care unit.40,63-65 If the patient presents during influenza season, 
testing for viral upper respiratory infections is recommended. 
Neuromuscular weakness should be assessed with negative 
inspiratory force and forced vital capacity.65,66 Regarding 
imaging, chest radiograph demonstrates a sensitivity of 
approximately 75% for diagnosis of pneumonitis.63-66 Computed 
tomography (CT) is recommended with contrast. The 
findings on CT vary, including ground glass opacities (37%), 
cryptogenic organizing pneumonia, interstitial infiltrates, and 
pneumonitis not otherwise specified.65,66 
If an infiltrate is present but the patient is asymptomatic, 
the patient does not require therapy beyond discontinuing the 
checkpoint inhibitor and obtaining oncology follow-up. Patients 
with critical illness or grade 3-4 irAEs require other therapies.63-65 
In the patient with severe respiratory symptoms, empiric therapy 
with antimicrobials is recommended, as grade 3-4 pneumonitis 
will not be immediately diagnosable. Procalcitonin can be 
used in the critical care setting to determine whether antibiotics 
should be continued, but this laboratory assessment should not 
be used in isolation for determining need for initial antibiotics.1-5 
Pneumocystis jirovecii (PJP) can cause similar clinical and 
radiographic findings, and empiric treatment with trimethoprim-
sulfamethoxazole is recommended if the patient is at high 
risk with corresponding radiographic findings.63-65 Antifungal 
Figure 2. Chimeric antigen receptor (CAR) T-cell therapy process
1) T cells present in the blood are removed from the patient. 2) These T cells are incorporated with the gene-encoding specific antigen 
receptors. 3) This results in CAR receptors present on the surface of T cells. 4)These modified T cells are harvested and grown in a 
laboratory setting. 5) The engineered T cells are finally administered to the original patient. 
Modified from https://commons.wikimedia.org/wiki/File:CAR_T-cell_Therapy.svg. Accessed April 7, 2019. 
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Organ System Grade Definition Management Disposition
Dermatologic
Most common agents: 
anti-CTLA-4 inhibitors 
(Ipilimumab), 
especially melanoma, 
but also associated 
with anti-PD-1/PD-L1 
therapy 
1 - Nonlocalized, diffuse rash, 
< 10% BSA
- Mild pruritis
- Provide oral antihistamines, class 
I topical corticosteroid (class V/VI 
for face)
- Discharge with oncology 
follow- up and dermatology 
referral
- Provide return precautions
- If symptoms worsen, treat 
as grade 3/4
2 - Maculopapular rash with 10-
30% BSA
- Intense, widespread rash 
pruritis, may have excoriations
- Similar to grade 1
- Add systemic corticosteroids 
(prednisone 0.5-1 mg/kg/day)
- Similar to grade 1
- If symptoms worsen, treat 
as grade 3/4
3-4 - Maculopapular rash > 30% BSA
- Intense pruritis, limits ADLs, 
sleep
- Stevens-Johnson syndrome or 
toxic epidermal necrolysis
- Full thickness dermal 
ulceration or necrotic, bullous, or 
hemorrhagic findings
- Evaluate and exclude systemic 
hypersensitivity
- Obtain serum tests with CBC with 
differential, complete metabolic panel
- Provide systemic corticosteroids 
- Provide oral antihistamines and 
GABA agonist (pregabalin or 
gabapentin)
- Admit with monitoring
- Emergent dermatology 
consult
Gastrointestinal
Most common agents: 
anti-CTLA-4 inhibitors 
(Ipilimumab), but also 
associated with anti-
PD-1/PD-L1 therapy
1 - Diarrhea ≤ 4 stools/day
- Asymptomatic colitis
- Observe patient, obtain stool and 
serum studies
- May provide antidiarrheal 
medications, but no strong 
recommendations
- Ensure follow up with 
oncology as outpatient
- Provide return precautions
- Treat as grade 2 if 
worsening symptoms
2 - Diarrhea 4-6 stools/day
- Colitis with abdominal pain, 
blood/mucous in stool
- Observe patient if diarrhea only, 
obtain serum and stool studies 
- CRP, ESR, fecal calprotectin, 
lactoferrin, imaging optional
- Antidiarrheal medications not 
recommended
- If diarrhea and colitis present, 
provide prednisone 1 mg/kg/day
- Obtain follow up with 
oncology
- Provide return precautions
- If no improvement in 2 
days, increase prednisone 
to 2 mg/kg/day
3-4 - Diarrhea > 7 stools/day, 
incontinence, requiring IV fluids for 
> 1 day, unable to do ADLs
- Colitis with severe pain, ileus, 
fever
- Grade 4 with peritoneal findings
- Admit patient, obtain serum and 
stool markers, inflammatory markers, 
imaging, and GI consult
- Prednisone 1-2 mg/kg/day
- Provide antibiotics
- May require other anti-inflammatory 
medications
- Oncology and GI consult 
with admission
- Infliximab may be needed 
(do not use in perforation 
or septic shock)
Hepatitis
Most common 
agents: combined 
anti-CTLA-4 inhibitor 
plus anti-PD-1/
PD-L1 therapy; 
isolated therapy less 
commonly associated
1 - Elevated AST, ALT to 3 X ULN 
- Elevated total bilirubin up to 1.5 
X ULN
- Evaluate and exclude infection, 
drug injury, thrombotic, or malignant 
causes
- Follow up with oncology 
or primary provider for 
repeat examination and 
testing
2 - Elevated AST, ALT > 3 X ULN 
to 5 X ULN 
- Elevated total bilirubin 1.5 X 
ULN to 3 X ULN
- Evaluate and exclude infection, 
drug injury, thrombotic, or malignant 
causes
- Prednisone 0.5-1 mg/kg/day
- Follow up with oncology 
or primary provider for 
repeat examination and 
testing in 1-2 days
3-4 - Elevated AST, ALT > 5 X ULN 
- Elevated total bilirubin > 3 X 
ULN
- Prednisone 1-2 mg/kg/day
- Provide antibiotics for 
opportunistic infections
- Consult GI
- Admit patient
- If patient does not 
improve in 3-5 days, other 
immunosuppressant 
medications needed
Table 2. Immune-related adverse effects on the organs of cancer patients undergoing immunotherapy.35-42,48,49 
therapy is reasonable in the intensive care unit (ICU) if patients 
do not improve despite use of other therapies. Regarding 
pneumonitis, 1-2 mg/kg/day of prednisone or methylprednisolone 
is recommended. Over 80% of patients will improve in several 
days if an irAE is present.67,68 However, up to 14% of patients 
will not respond to corticosteroid therapy.37,67 Higher doses can 
be attempted (4 mg/kg/day), as well as other agents including 
infliximab or mycophenylate.37
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Table 2. Continued. 
Organ System Grade Definition Management Disposition
Pulmonary
Most common 
agents: 
combined anti-
CTLA-4 inhibitor 
plus anti-PD-1/
PD-L1 therapy; 
isolated therapy 
less commonly 
associated
1 - Asymptomatic - Monitor symptoms/oxygen saturation
- Consider imaging before reinitiating 
checkpoint inhibitor
- Consider pulmonary, ID consult
- Ensure follow up with oncology 
as outpatient; provide return 
precautions
- If saturation falls < 92%, 
recommend home pulse oximetry
2 - Symptoms limiting ADLs, 
mild/moderate hypoxia
- Systemic corticosteroids (prednisone 1 
mg/kg/day)
- Consider prophylactic antibiotics
- Bronchoscopy or lung biopsy may be 
required
- Consider pulmonary, ID consult
- Discuss with oncology 
- Admit to observation unit
3-4 - Severe new symptoms, 
worsening/severe hypoxia
- Methylprednisolone 2 mg/kg/day IV
- Patients with severe symptoms may 
require infliximab, cyclophosphamide, IVIG, 
or mycophenolate
- Consider prophylactic antibiotics
- Bronchoscopy or lung biopsy may be 
required
- Consult pulmonary and ID 
specialists
- Admit with monitoring, 
consider ICU care
Nephritis
Less commonly 
affected than 
other systems; 
most commonly 
with combined 
anti-PD-1/PD-L1 
and anti-CTLA-4 
inhibitor therapy
1 - Asymptomatic
- Creatinine increase > 0.3 
mg/dL or Creatinine > 1.5 
-2 X ULN
- No treatment needed
- Consider discontinuing checkpoint inhibitor
- Follow up with oncology and 
obtain outpatient referral
2 - Creatinine > 2-3 X ULN - Discontinue checkpoint inhibitor
- Evaluate for other etiologies of renal injury 
with laboratory assessment and ultrasound
- Prednisone 0.5-1 mg/kg/day
- Follow up with oncology and 
obtain nephrology referral
3-4 - Creatinine > 4 mg/dL or 
Creatinine > 3 X ULN
- Grade 4 marked by 
life-threatening electrolyte 
abnormalities
- Discontinue checkpoint inhibitor
- Evaluate for other etiologies of renal injury 
with laboratory assessment and ultrasound
- Prednisone 1-2 mg/kg/day
- Biopsy typically required
- Admit to hospital
- Consult oncology and 
nephrology specialists
Endocrine
Most common 
agents: anti-
PD-1/PD-L1 
therapy and anti-
CTLA-4 inhibitor 
therapy
1 - Asymptomatic or mild 
symptoms
- No treatment needed - Follow up with oncology and 
obtain outpatient endocrine 
referral
2-3 - Evidence of endocrine 
dysfunctions with 
weakness, fatigue
- Treat based on condition
- Hypophysitis: Obtain TSH, T4, cortisol; MR 
sella; prednisone 1-2 mg/kg/day if imaging 
abnormal
- Adrenal insufficiency (central): 
hydrocortisone 100 mg IV
- Diabetes (insulin-dependent): Start insulin, 
evaluate for DKA
- Hypothyroidism: Start levothyroxine
- Hyperthyroidism: Treat with beta-blockers 
if symptoms present, treat Graves’ disease 
if present
- Endocrinology consult
- Admit to hospital
4 - Adrenal crisis may be 
present (dehydration, 
shock)
- Visual field deficits, severe 
headache
- Evaluate and exclude sepsis
- Manage adrenal crisis (hydrocortisone)
- Resuscitate with IV fluids
- Treat with prophylactic antibiotics
- Emergent endocrinology 
consultation
- Admit to ICU for further 
evaluation and monitoring
CTLA4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; BSA, body surface 
area; GABA, gamma-aminobutyric acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ADLs, activities of daily living; mg, 
milligram; kg, kilogram; CBC, complete blood count, GI, gastrointestinal; ID, infectious diseases; IV intravenous; IG, immunoglobulin; MR, 
magnetic resonance; TSH, thyroid stimulating hormone; ULN, upper limit of normal; ICU, intensive care unit; DKA, diabetic ketoacidosis; CRP, 
C-reactive protein; ESR, erythrocyte sedimentation rate.
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Patients with grades 3-4 pneumonitis or critical illness will 
require ICU admission. Bronchoscopy may be needed; however, 
there is no specific finding on bronchoscopy that definitely 
diagnoses pneumonitis due to checkpoint inhibitor toxicity, and it 
is not associated with improved survival.56,57,66-68  Bronchoscopy 
can be used to evaluate for infection as the etiology.56,57 The 
decision for bronchoscopy is ultimately left to the pulmonologist 
and critical care physician. 
Gastrointestinal Presentations
GI presentations of irAE typically include diarrhea and 
colitis, which can occur in up to 40% on ipilimumab.1-4 These 
most often occur 6-7 weeks after initiation of therapy.1-4,40 In 
the ED, differentiating mild-moderate symptoms from severe 
diarrhea and colitis is vital, as well as considering the wide 
differential including infectious diarrhea, enteritis, inflammatory 
bowel disease, and perforation. Nausea and vomiting may be 
present with upper GI tract involvement. Colitis tends to present 
with pancolitis, diverticulosis and segmental colitis, or isolated 
rectosigmoid colitis but no diverticulosis.70 Severe colitis with 
fever, peritonitis, and perforation is rare but may occur.57,58,71 
Stool testing is recommended based on the grade of severity to 
include bacterial pathogens, viral etiologies, and Clostridium 
difficile.57,58,70,71 Imaging with CT of the abdomen/pelvis is 
recommended in patients with critical illness to evaluate 
disease severity and complications and may demonstrate 
thickening of the bowel wall, mesenteric fullness, stranding, 
and/or perforation.70-73 Colonoscopy for patients with severe 
illness may be used to evaluate for alternative diagnoses and 
guide management. Upper endoscopy may be needed during 
admission if CT does not reveal findings of colitis but the 
patient has diarrhea.72,73 
Volume-depleted patients require fluid resuscitation. 
Opioids and medications such as loperamide should be 
avoided, if possible. Corticosteroids are recommended for 
patients with > 6 stools, patients who are admitted for colitis, 
and other complications, with prednisone at doses of 1-2 mg/
kg/day.37,57,58,73,74 Patients with severe disease may require 
infliximab.37,57 Patients with perforation or toxic megacolon 
require surgical consultation. Empiric antibiotics are 
recommended for those with severe illness.
Hepatitis
Patients with hepatitis due to an irAE are usually 
asymptomatic and detected by routine liver function assessments, 
although patients may present with fever, jaundice, and 
abdominal pain.37,75 Immune-related adverse events affecting the 
liver typically occur 6-14 weeks after beginning therapy.35-37,75 
Liver function tests including aspartate transaminase and alanine 
aminotransferase, as well as bilirubin, are increased, and the 
symptoms and levels of elevation determine the severity.37,75 
Fulminant hepatic failure and death are rare. Evaluating for 
other conditions is recommended, such as alcoholic hepatitis, 
acetaminophen toxicity, viral hepatitis, chronic hepatitis 
reactivation, biliary obstruction, shock liver, liver metastases, or 
vascular occlusion. Laboratory assessment should include viral 
hepatitis panel and autoimmune hepatitis panel (anti-smooth 
muscle antibodies, antinuclear antibody, liver-kidney microsomal 
antibody). Ultrasound of the liver, gallbladder, and biliary tract 
with doppler examination is needed to evaluate for liver and/
or biliary disease.37,75  Treatment includes stopping medications 
that may result in hepatoxicity. Those with grade 2 disease or 
higher should receive corticosteroids. Infliximab may result in 
hepatotoxicity, limiting its use in hepatitis due to irAE.2,35-37
Nephritis
Acute tubulointerstitial nephritis is the most common 
form of renal toxicity, although glomerulonephritis can also 
occur.2,35-40 Patients are typically asymptomatic, with laboratory 
abnormality the only finding. Renal failure can present with 
uremic encephalopathy, volume overload, and electrolyte 
abnormalities.2,76,77 As renal injury due to irAE is rare, evaluation 
for other causes of renal failure is recommended to include CBC 
and blood smear (microangiopathic hemolytic anemias), CK 
(myositis and rhabdomyolysis), and urinalysis are recommended. 
Urinalysis may be normal or include sterile pyuria, mild 
proteinuria, microscopic hematuria, and granular casts.76,77 
Renal ultrasound is recommended with vascular studies. If no 
other cause is found for renal injury, biopsy is recommended. 
Corticosteroids should be initiated if the renal injury is due to 
irAE. Other immunosuppressant medications may be needed if 
the patient does not improve. Hemodialysis is recommended for 
grade 4 irAEs.2,35-40,76,77
Endocrinopathies
Endocrinopathy affects approximately 10% of patients; it 
can be either central involving the pituitary gland, or peripheral 
involving the thyroid or adrenal glands.2,48 Immune-related 
adverse events affecting the endocrine system are difficult to 
diagnose, and clinicians should consider these conditions in 
patients with non-specific symptoms such as fatigue, weakness, 
headache, nausea, and vomiting.2,40,48,54 These complications 
typically arise 9-10 weeks after initiation of therapy. 
Endocrinopathies differ from other irAEs with organ dysfunction, 
as treatment with corticosteroids is not typically used, and 
organ dysfunction is often persistent due to disruption of the 
adrenal axis.2,35-40,61 Thus, treatment typically involves hormone 
replacement on a long-term basis. 
Primary hypothyroidism is the most common endocrinopathy 
and may present with fatigue, cold intolerance, weight gain, 
constipation, and depression.2,37,48,78 Diagnosis involves elevated 
TSH and low free T4, and treatment includes thyroid hormone 
replacement. Hyperthyroidism comes in two forms: thyroiditis 
and Graves’ disease. Symptoms of hyperthyroidism include 
heat intolerance, diaphoresis, dyspnea, diarrhea, palpitations, 
tremor, and weight loss, although Graves’ disease can present 
with ophthalmopathy.2,40,48,79 Thyroiditis presents with mild 
symptoms of hyperthyroidism in the acute phase, followed by 
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chronic hypothyroidism due to gland destruction. Graves’ disease 
is much less common and presents with persistent, more severe 
hyperthyroidism.2,48,79 Diagnosis includes reduced TSH and 
elevated free T4. TSH-receptor antibody can be used as well. 
Treatment includes a thionamide and endocrinology consult for 
those with mild-moderate symptoms.2,37,40 Severe symptoms 
require therapy for thyrotoxicosis and thyroid storm if present, as 
well as corticosteroids.37 
Adrenal insufficiency can present with fatigue and weight 
loss or with adrenal crisis and distributive shock. Electrolytes, 
renal and liver function, cortisol, adrenocorticotropic hormone 
(ACTH), and CT of the abdomen/pelvis are recommended. 
Treatment includes hydrocortisone, with dosing dependent 
on patient hemodynamic status and symptoms. Adrenal crisis 
requires hydrocortisone 100 mg IV, as well as evaluation 
for infection, broad-spectrum antibiotics, and IV fluids with 
glucose.2,35-40,48 
Pituitary dysfunction, or hypophysitis, typically presents 
with symptoms of hypothyroidism but may also present with 
arthralgias, vision changes, hypogonadism, hypothyroidism, 
diabetes insipidus, and/or adrenal insufficiency.2,35-40,48,54,79 
Headache occurs in 85% of patients.40 Electrolytes, cortisol, 
ACTH, TSH, free T4, luteinizing hormone, follicle-
stimulating hormone, and either testosterone/estrogen level 
are recommended, as well as central nervous imaging with 
brain MRI.37-40 Diagnosis is based on at least one hormone 
deficiency plus MRI abnormality, or > 2 hormone deficiencies 
with headache.37-40 Treatment is based on patient presentation, 
symptoms, and laboratory results.37,40 Insulin-dependent 
diabetes is another irAE.2,37,80 Treatment focuses on insulin and 
management of diabetic ketoacidosis if present.37 
Neurologic
Neurologic irAEs are rare (1-6%) but may include 
myasthenia gravis with fatigable and fluctuating weakness 
primarily affecting ocular and bulbar muscles.40,81-86 Conditions 
that may present in a similar manner include myositis, spinal 
cord pathology, and Guillain-Barré syndrome (Miller-Fisher 
variant).81-85 Laboratory assessment includes CK, electrolytes, 
and MRI of the brain and/or spine dependent on the patient 
presentation.81-86 Admitted patients should be tested for 
acetylcholine receptor and anti-striated muscle antibodies, as well 
as electrodiagnostic studies. Treatment includes prednisone 1-1.5 
mg/kg/day and pyridostigmine. Intravenous immunoglobulin 
(IVIG) or plasmapheresis for severe symptoms is 
recommended.81-86 Medications such as beta blockers, magnesium 
IV, fluoroquinolones, macrolides, and other medications that can 
worsen myasthenia must be avoided. 
Guillain-Barré syndrome can present with progressive, 
ascending muscle weakness, often beginning with neuropathic 
pain and/or sensory changes in the lower extremities.2,37,81,83,87 
Reflexes are typically absent. This disease may cause respiratory 
failure with respiratory muscle involvement and dysautonomia. 
CK, spine MRI, lumbar puncture (LP) (elevated protein), and 
electrodiagnostic studies are recommended.88-90 Treatment 
includes IVIG or plasmapheresis.87-90
Transverse myelitis presents with bilateral acute/subacute 
weakness or sensory changes.89,90 Reflexes are increased, as 
opposed to Guillain-Barré syndrome.40,81-85 Assessment with MRI 
of the spine and LP is recommended, with management including 
methylprednisolone 2 mg/kg/day or 1 g/day IV.81-85,90
Encephalitis may present with confusion, headache, 
seizures, focal weakness, or other focal findings such as altered 
speech.2,37,81,83 LP with central nervous system imaging is 
recommended. LP may reveal lymphocytic pleocytosis and 
elevated protein, and imaging is often normal, although brain 
MRI may reveal T2-weighted-fluid-attenuated inversion recovery 
signals.89-91 Patients should be treated with antibiotics and 
acyclovir until infection is excluded.40,81-85 Methylprednisolone 
1-2 mg/kg IV is recommended, although patients with the 
presence of severe symptoms or oligoclonal bands should be 
managed with methylprednisolone 1 g with IVIG.81-85 
Other neurologic conditions include neuropathies, aseptic 
meningitis, multiple sclerosis, optic neuritis, and posterior 
reversible encephalopathy syndrome.81-85,90,91 
Hematologic
Checkpoint inhibitors can affect all blood cell lines, 
resulting in a variety of hematologic abnormalities.92-102 Anemia 
can be due do an autoimmune hemolytic type or aplastic.92-97 
Autoimmune hemolytic anemia can present with weakness, 
jaundice, pallor, dark urine, and fatigue. Evaluation includes CBC 
with differential, peripheral smear, reticulocyte count, lactate 
dehydrogenase, haptoglobin, coagulation panel, fibrinogen, and 
direct agglutinin test.92-96 Treatment for confirmed hemolytic 
anemia includes prednisone 1-2 mg/kg/day with folic acid. 
Transfusion with irradiated and filtered products is recommended 
if hemoglobin is < 7 milligrams per deciliter (mg/dL).32,92-97 
Immune thrombocytopenia presents with petechiae and 
bleeding.2,37,97,98 Laboratory assessment is similar to that in 
hemolytic anemia, though testing for HIV and hepatitis B/C is 
recommended. Treatment includes prednisone and IVIG. Bone 
marrow aspiration may be required during admission.2,37,97,98 
Lymphopenia may lead to opportunistic infections such 
as Pneumocystis jirovecii pneumonia (PJP), as well as other 
infections similar to human immunodeficiency virus (HIV).2,3,37,97-
100 Patients should be evaluated for HIV and cytomegalovirus 
(CMV). Chest radiograph, HIV testing, and CD4 T cell count are 
recommended.2,3,37,97 If patients present with a lymphocyte count 
< 250 cells per millimeter cubed (cells/mm3), then prophylaxis 
for PJP and mycobacterium avium complex is recommended. 
Aplastic anemia presents with findings of anemia, 
thrombocytopenia, and lymphopenia/neutropenia.2,3,97-101 
Evaluation for viral diseases such as CMV, Epstein-Barr virus, 
HIV, and parvovirus is recommended, along with B12/folate 
levels and bone marrow aspiration during admission. Patients 
with severe aplastic anemia without a clear secondary cause may 
require anti-thymocyte globulin and cyclosporine.2,3,40,97-101 
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A dangerous hemolytic irAE is acquired thrombotic 
thrombocytopenic purpura (TTP) or atypical hemolytic uremic 
syndrome (aHUS).2,3,40,92,97 Both conditions can present with 
non-palpable purpura, fever, abdominal pain/vomiting, and renal 
failure. TTP tends to present with neurologic abnormalities. 
Lactate dehydrogenase, haptoglobin, coagulation panel, 
fibrinogen, ADAMTS13 activity and inhibitor titer, complement, 
and urinalysis are recommended, along with the other common 
laboratory assessments for anemia. If diarrhea is present, testing 
for bacterial pathogens is recommended. Treatment depends on 
the diagnosis. Prednisone or methylprednisolone can be used, 
but for TTP, plasma exchange is recommended, while for aHUS 
eculizumab is recommended.2,3,40,92,97 
Acquired hemophilia can occur due to inhibition of factor 
VIII.97,101,102 Mixing studies and quantification of inhibitor levels 
are used to make the diagnosis. Treatment includes prednisone 
and/or other immunosuppressive therapies.37,97 
Rheumatologic
Myalgias and arthralgias are present in 2-12% of patients, 
most commonly in those receiving anti-PD-1 agents.37,40,91 
However, vasculitis, myositis, and giant cell arteritis may occur. 
Patients with mild to moderate symptoms can be treated with 
acetaminophen and/or non-steroidal anti-inflammatory drugs. 
Prednisone can also be used. Severe symptoms should be treated 
with high-dose corticosteroids, with consultation with oncology 
and rheumatology.2,3,37,40,91 
Ocular
Ocular toxicity is rare, occurring in 1% of patients.2,3,103 
These are divided into ocular inflammation including keratitis, 
uveitis and orbital inflammation, and retinal/choroidal disease. 
Patients may present with eye pain and vision changes. Treatment 
requires ophthalmology consultation with topical corticosteroids 
for episcleritis or anterior uveitis. Systemic corticosteroids are 
recommended for severe inflammation.2,3,103 
Unique Toxicities of CAR T-Cell Therapy 
Regarding CAR T-cell therapy, B cell aplasia is common 
with use of CD19-directed CAR T-cell therapy, given 
that CD19 is all expressed on normal mature B cells.23-27 
Hypogammaglobulinemia may be present due to B cell depletion. 
Other hematologic toxicities can occur such as anemia or 
thrombocytopenia.23-27 Major side effects include cytokine release 
syndrome (CRS) and neurologic effects such as CAR T-cell-
related encephalopathy syndrome (CRES).27,104-106 
CRS occurs with massive release of cytokines.104-106 It 
may affect up to 90% of patients receiving CAR T-cell therapy, 
with half severe, requiring critical care and vasopressors and/
or ventilation.107-110 Cytokines are proteins that act as signaling 
among cells and result in systemic inflammation. Interleukin 
(IL)-1 and IL-6 are central factors in CRS toxicity.110-115 This 
may result in a variety of symptoms, ranging from mild flu-like 
symptoms to hypotension and death (Table 3).104-106 Symptom 
onset in CRS varies, depending primarily on the agent and 
severity of immune cell activation. CRS most commonly 
occurs one to five days after CAR T-cell infusion, although it 
may occur weeks later.104-115 Patients with large tumor burdens 
may experience more severe symptoms. There is no correlation 
between CRS and clinical response to therapy.104-106 
As Table 3 demonstrates, signs and symptoms of CRS 
overlap with sepsis, macrophage activation syndrome 
(hemophagocytic lymphohistiocytosis), neutropenic fever, and 
tumor lysis syndrome.104-106,116-120 Due to the increased levels of 
inflammatory markers, patients develop systemic inflammation, 
beginning with fever, which may reach over 40.0° C.121 Fever 
usually precedes the onset of CRS by at least one day.104-106,116-
120 Those with fever receiving CAR T-cell therapy should be 
admitted and monitored for CRS. The severity can range from 
mild, treated with supportive care, to life-threatening, with a wide 
variety of signs and symptoms.104-106,116-120 Flu-like symptoms such 
as fatigue, headache, rash, arthralgias, and myalgias are common. 
Severe cases can include hypotension and shock, disseminated 
intravascular coagulation, and multiorgan failure.104-106,116-120 
Respiratory symptoms such as cough and tachypnea can progress 
to acute respiratory distress syndrome. Cardiac toxicity can be 
life-threatening and presents in a similar manner to sepsis or 
stress cardiomyopathy; however, it is often reversible.104-106,122,123 
The NCI has developed a grading system for severity 
(Table 4).104-106 Laboratory results often reveal elevated liver 
function tests and bilirubin, increased or decreased white blood 
cells and platelets, low fibrinogen, elevated blood urea nitrogen 
(BUN), and increased D-dimer. Chest radiograph, urinalysis, 
and blood cultures are recommended due to the high risk of 
infection.104-106,118 C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) may be elevated, but normal results 
cannot exclude CRS. CRP is often elevated in CRS, as it is 
Organ System Patients signs and symptoms
Constitutional Fever, fatigue, malaise, myalgias, arthralgias, 
anorexia
Cardiac Tachycardia, hypotension, wide pulse pressure, 
cardiac dysfunction, cardiomyopathy
Dermatologic Rash, pruritis
Pulmonary Tachypnea, hypoxemia, dyspnea, acute 
respiratory distress síndrome
Gastrointestinal Nausea/vomiting, diarrhea, transaminitis, 
elevated bilirubin, jaundice
Renal Decreased urine output, azotemia, renal injury
Vascular Hypofibrinogenemia, elevated D-dimer, 
coagulopathy, bleeding, disseminated 
intravascular coagulation
Neurologic Headache, confusion, altered mental status, 
delirium, aphasia, hallucination, tremor, seizure, 
dysmetria, ataxia
Table 3. Cytokine release syndrome (CRS) signs and symptoms.104-106
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associated with IL-6 production117,124-127 However, CRP cannot 
differentiate between CRS and infection.124-127 While not typically 
obtained in the ED, ferritin is often elevated in CRS, similar to 
that seen in macrophage activation syndrome.104-106,128 
Management of CRS requires symptomatic care and 
cytokine inhibition. Depending on signs, symptoms, and 
patient hemodynamic status, patients may require IV fluids, 
vasopressors, and broad-spectrum antibiotics, as sepsis is 
possible (Table 4).104-106,117,118 Management of CRS focuses on 
two medications: corticosteroids and tocilizumab, a humanized 
immunoglobulin that prevents IL-6 binding to other receptors 
and further cell signaling.104-106 Literature suggests tocilizumab 
is an effective therapy for severe CRS, with improvement 
within hours of infusion.129-131 Corticosteroids are generally 
avoided in CRS and should only be used in conjunction with 
oncology consultation, as these medications can adversely affect 
antitumor effects. This differs from checkpoint inhibitor therapy, 
in which corticosteroids do not affect the therapeutic effects on 
the malignancy.117,132,133 However, if evidence of adrenal crisis is 
present, stress-dose corticosteroids are recommended. Patients 
with CRS require admission and consultation with oncology due 
to the potential severe nature of the condition.104-106 
Differentiating CRS from infection and sepsis is difficult, 
as patients will typically meet systemic inflammatory response 
syndrome criteria and have greater than two points on the 
sequential organ failure assessment score.118,121 One study found 
that 23% of patients developed infection in the first month of 
CAR T-cell therapy, with many infections occurring with onset 
of CRS.118 Bacterial infections predominate, primarily of the 
respiratory tract. Thus, patients should be presumed to have 
infection, and antibiotics and resuscitation are recommended in 
the ED.104-106 
Cytokine storm is due to nonspecific activation of T cells, 
usually rapidly after CAR T-cell infusion.119,120  This condition is 
a separate entity from CRS, although the presentation is similar. 
Tumor necrosis factor and interferon gamma are the predominant 
factors resulting in cytokine storm.104-106,119,120 As opposed to CRS, 
the primary therapy for cytokine storm includes corticosteroids 
with resuscitation. However, corticosteroids should only be 
initiated with oncologist consultation, as steroids can deplete 
CAR T-cells.104-106
Neurologic complications from CAR T-cell therapy present 
in a wide range, from mild headache to severe altered mental 
status and seizures.104,120 Neurotoxicity is the second most 
common major adverse event with CAR T-cell therapy, officially 
known as CRES.104-106 CRES does not always coincide with 
CRS, and symptoms can occur before, during, or after CRS.104 
A mechanism has not been definitely determined, although IL-1 
may play a role. Tocilizumab is not effective in CRES as it does 
not cross the blood–brain barrier; however, anakinra, which 
blocks IL-1 receptors, may be beneficial.105 Patients with severe 
neurologic symptoms should be managed with corticosteroids, 
primarily dexamethasone 10 mg IV due to its ability to cross the 
blood–brain barrier.104,134
What’s the Emergency Physician to Do? 
While irAEs from checkpoint inhibitors and complications 
of CAR T-cell therapy can be severe, physicians must 
consider several other causes of the patient’s symptoms. 
Patients may be experiencing acute illness unrelated to the 
malignancy and therapy, complications of the malignancy 
itself (disease progression or other complication such as tumor 
lysis syndrome), complications of more traditional cancer 
therapies including chemotherapy and radiotherapy (radiation 
pneumonitis, opportunistic infections/neutropenic fever), and 
complications of the immune-based therapy itself (irAEs, 
underlying rheumatologic disorder, immune reconstitution 
syndrome).1-3,12,35-40 With this wide differential of potentially 
dangerous conditions, patients may require emergent 
resuscitation. 
Obtaining history of immune-based therapy is vital in the 
consideration of irAEs, CRS, or CRES. In the ED, biomarkers 
Grade Toxicity/Symptoms Treatment
1 Symptoms are not life-threatening and include fever, nausea, 
fatigue, headache, myalgias
Provide symptomatic therapy, assess for infection, 
can continue infusion
2 Symptoms require but respond to moderate intervention:
-Oxygen requirement < 40% or 
-Hypotension responsive to fluid or low dose of one vasopressor or 
-Grade 2 organ toxicity
Discontinue infusion, provide oxygen and 
symptomatic therapy (acetaminophen, IV fluids, 
NSAIDs), assess for infection
3 Symptoms require and respond to aggressive intervention:
-Oxygen requirement > 40% or 
-Hypotension requiring high dose or multiple vasopressors or
-Grade 3 organ toxicity or grade 4 transaminitis
Stop infusion, treat for infection, admit patient, 
provide oxygen, administer fluids and vasopressors, 
consider tocilizumab with steroids
4 Life-threatening symptoms:
-Requirement for ventilator support or
-Grade 4 organ toxicity (excluding transaminitis)
Treat as Grade 3, treat other complications 
(ventilator support often required)
5 Death
Table 4. Grading cytokine release syndrome to guide treatment.104-106
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such as interleukin levels are not readily available. Laboratory 
assessment should include CBC with differential, renal function 
and electrolytes, coagulation studies, liver function testing, 
cortisol, TSH, and urinalysis. Inflammatory markers such as CRP 
and ESR may be beneficial but cannot definitively diagnose the 
condition or exclude infection. Suspicion of an infectious etiology 
requires blood cultures and antibiotics. Bedside echocardiography 
can assist in assessment of the cardiopulmonary system.1-4,12,35-40 
Management focuses on the specific organ involved, 
with resuscitation and antibiotics. For severe, critical illness, 
the checkpoint inhibitor should be discontinued if an irAE is 
likely. Early initiation of a corticosteroid improves prognosis 
with irAEs due to checkpoint inhibitors, except for those with 
endocrinopathies, and most patients improve within 2-3 days. 
If patients do not improve, there are other immunosuppressive 
agents that can be used.1-3,71 Recurrence of an irAE can be 
seen with corticosteroid tapering and checkpoint inhibitor 
reinitiation.1-3,12,37  Regarding CRS related to CAR T-cell therapy, 
patients should be admitted to the ICU for tocilizumab, and 
CRES requires ICU admission and corticosteroids.35-40
CONCLUSION
Immune-based therapies consist of immune stimulators, 
checkpoint inhibitors, and adoptive immunotherapy. These 
therapies differ in mechanism compared to other anticancer 
therapies, namely chemotherapy and radiation. Complications 
include irAEs, CRS, autoimmune toxicity, and CRES. Immune-
related adverse events, most commonly encountered with 
checkpoint inhibitors, may result in dermatologic complications, 
pneumonitis, colitis/diarrhea, hepatitis, and endocrinopathies. 
Less common irAEs include nephritis, myocardial injury, 
neurologic toxicity, ocular diseases, and musculoskeletal 
complications. Cytokine release syndrome and CRES are more 
commonly associated with CAR T-cell therapy. Cytokine release 
syndrome may present with flu-like illness, but severe myocardial 
and pulmonary disease may occur. Critically ill patients require 
resuscitation, broad-spectrum antibiotics, and hematology/
oncology consultation.
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